(Q37367325)

English

Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies

scientific article published on January 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

1 reference

Europe PubMed Central

Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

inflammatory bowel diseases

0 references

0 references

0 references

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

bioavailability

1 reference

based on heuristic

inferred from title

Mark A Ainsworth

2

object named as

Mark Ainsworth

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Casper Steenholdt

3

object named as

Casper Steenholdt

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

author name string

Klaus Bendtzen

1

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Ole Østergaard Thomsen

4

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Jørn Brynskov

5

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

publication date

1 January 2009

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Scandinavian Journal of Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

44

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

774-781

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Inflammatory bowel disease: clinical aspects and established and evolving therapies

1 reference

https://api.crossref.org/works/10.1080%2F00365520802699278

21 January 2018

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1080%2F00365520802699278

21 January 2018

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

1 reference

https://api.crossref.org/works/10.1080%2F00365520802699278

21 January 2018

Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1080%2F00365520802699278

21 January 2018

Rationally engineered therapeutic proteins with reduced immunogenicity.

1 reference

https://api.crossref.org/works/10.1080%2F00365520802699278

21 January 2018

Immunogenicity of engineered antibodies

1 reference

https://api.crossref.org/works/10.1080%2F00365520802699278

21 January 2018

Immunogenicity of protein therapeutics

1 reference

https://api.crossref.org/works/10.1080%2F00365520802699278

21 January 2018

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F00365520802699278

21 January 2018

Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1080%2F00365520802699278

21 January 2018

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

https://api.crossref.org/works/10.1080%2F00365520802699278

21 January 2018

Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation

1 reference

https://api.crossref.org/works/10.1080%2F00365520802699278

21 January 2018

Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial

1 reference

https://api.crossref.org/works/10.1080%2F00365520802699278

21 January 2018

Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges

1 reference

https://api.crossref.org/works/10.1080%2F00365520802699278

21 January 2018

Variability factors in the clinical response to recombinant antibodies and IgG Fc-containing fusion proteins

1 reference

https://api.crossref.org/works/10.1080%2F00365520802699278

21 January 2018

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

1 reference

https://api.crossref.org/works/10.1080%2F00365520802699278

21 January 2018

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

1 reference

https://api.crossref.org/works/10.1080%2F00365520802699278

21 January 2018

Anti-IFN BAb and NAb antibodies: a minireview

1 reference

https://api.crossref.org/works/10.1080%2F00365520802699278

21 January 2018

Antibody pharmacokinetics and pharmacodynamics

1 reference

https://api.crossref.org/works/10.1080%2F00365520802699278

21 January 2018

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

1 reference

https://api.crossref.org/works/10.1080%2F00365520802699278

21 January 2018

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://api.crossref.org/works/10.1080%2F00365520802699278

21 January 2018

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

1 reference

https://api.crossref.org/works/10.1080%2F00365520802699278

21 January 2018

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

1 reference

https://api.crossref.org/works/10.1080%2F00365520802699278

21 January 2018

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

1 reference

https://api.crossref.org/works/10.1080%2F00365520802699278

21 January 2018

American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.

1 reference

https://api.crossref.org/works/10.1080%2F00365520802699278

21 January 2018

Infliximab treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1080%2F00365520802699278

21 January 2018

Identifiers

10.1080/00365520802699278

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37367325&oldid=1809895784"